Loading...
Pfizer Inc (PFE) is set to release its FY2025Q3 earnings performance on 11/04 05:00:00 in Pre-Market trading. Consensus forecasts predict a revenue of 17.00B and an earnings per share (EPS) of 0.66 for the FY2025Q3. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
Pfizer's Q3 earnings are expected to be neutral due to mixed factors such as growth in oncology offset by pricing pressures and waning COVID vaccine demand.

The Fact Data presents a mixed picture for Pfizer’s Q3 earnings, with offsetting positive and negative drivers:
Positive Phase 3 EV-303 trial results for Padcev + Keytruda in bladder cancer (60% reduction in tumor recurrence risk, 50% death risk reduction) could drive near-term revenue upside for this key product.
Padcev is part of Pfizer’s core oncology portfolio, which is critical for offsetting patent cliffs.
FDA acceptance of vepdegestrant’s NDA (Prescription Drug User Fee Act date: June 2026) signals confidence in the breast cancer candidate’s potential.
Collaboration with C4 Therapeutics on elranatamab (multiple myeloma) adds optionality to the oncology pipeline.
The Trump administration’s “most favored nation” pricing agreement requires Pfizer to offer U.S. discounts (up to 85% on some drugs), directly pressuring gross margins.
Recent FDA biosimilar guidance accelerates competition, risking long-term pricing power.
Enanta’s EU patent lawsuit over Paxlovid could lead to future liabilities.
COVID vaccine demand continues to wane (CDC ends universal recommendations), reducing revenue contribution.
Cost Management: Workforce reductions at Arvinas (15% cuts) and refocused R&D spending suggest operational discipline, but $70B U.S. investment plan raises long-term capex.
Mixed Analyst Sentiment: While Morgan Stanley and BofA maintain neutral ratings, Padcev’s success and Metsera’s obesity pipeline provide cautious optimism.
Rationale: Consensus reflects lowered expectations, but lack of clear catalysts (Padcev growth vs. pricing headwinds) favors a neutral outcome.
The earnings call shows strong revenue growth and a solid cash position, with a positive outlook on lithium pricing and strategic diversification through the Tungsten acquisition. The share buyback program and lack of debt further strengthen the financial health. Despite some uncertainties in shipment timing and royalty transaction timelines, the company's focus on high-return projects and stable long-term lithium demand support a positive sentiment.
The earnings call summary and Q&A indicate strong strategic moves and financial health. Pfizer's R&D productivity, cost savings initiatives, and raised EPS guidance are positive indicators. The Q&A revealed confidence in key trials and strategic legal actions. Despite some unclear responses, the overall sentiment is positive, with optimistic guidance and strategic expansions in multiple markets. The lack of market cap data limits precise impact prediction, but the positive factors outweigh negatives, suggesting a positive stock price movement.
Pfizer Inc (PFE) is scheduled to release its FY2025Q3 earnings report onNov 4, 2025, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
Analysts' consensus predicts 17.00B in revenue and an EPS of 1.00 for Pfizer Inc's FY2025Q3.
Intellectia's exclusive AI algorithms forecast a Neutral forPfizer Inc's FY2025Q3 earnings, with a prediction date of Nov 4, 2025. Pfizer Inc Pfizer's Q3 earnings are expected to be neutral due to mixed factors such as growth in oncology offset by pricing pressures and waning COVID vaccine demand.
Leverage Intellectia's AI forecast to position trades ahead of theNov 4, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
Each prediction includes a detailed rationale, key indicator forecasts, and scenario probabilities to guide your trades. For a *Beat*, consider buying call options or shares; for a *Miss*, explore puts or hedging strategies. The prediction card provides actionable suggestions, like specific option strikes or hedging tips, tailored to your risk tolerance. Trade smart and turn insights into profits!